Objective The partners aim to develop a point-of-care diagnostic test using recombinant technology. More specifically, the aim is to develop a test for the detection of antibodies to the malarial parasite using uniquely identified recombinant proteins derivative from the tachyzoite stage of the malarial parasite found in human blood. The diagnostic test format is envisaged to be lateral flow blood test, which will lend itself to low manufacturing costs. Whilst in a European market packaged format the product will be presented through traditional channels, a less sophisticated test presentation will allow the test to be affordable to the primary world areas where the malarial disease is of fundamental economic and health importance. This novel format will require the development of a new test device which will result in a rapid, (less than 5 minutes) accurate, sensitive and specific test which is easy to use and can be developed for further tests. Fields of science medical and health scienceshealth sciencesinfectious diseasesmalarianatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsengineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-2. - Key action Control of Infectious Diseases Call for proposal Data not available Funding Scheme EAW - Exploratory awards Coordinator BIO - DIAGNOSTICS LTD EU contribution No data Address Upton Industrial Estate, Rectory Road WR8 0LX UPTON-UPON-SEVERN United Kingdom See on map Total cost No data Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all DIARECT A.G. Germany EU contribution No data Address Boetzinger Strasse 29B 79111 FREIBURG (IN BREISGAU) See on map Total cost No data
